secwatch.observer — SEC 8-K summary
======================================

Issuer:     SELLAS Life Sciences Group, Inc. (SLS)
CIK:        0001390478
Form:       8-K
Filed at:   2026-05-12T20:07:20+00:00
Accession:  0001390478-26-000009
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

SELLAS reports 78 events in REGAL AML trial; Q1 net loss $8.4M, cash $107.1M
----------------------------------------------------------------------------

- 78 events (deaths) occurred in pivotal Phase 3 REGAL trial of GPS in AML as of May 11; final analysis triggered at 80th event.
- Cash and cash equivalents $107.1M at March 31, 2026; additional $7.5M from warrant exercises received in Q2 2026.
- Net loss $8.4M for Q1 2026 ($0.05 per share) vs $5.8M loss ($0.07 per share) in Q1 2025.
- Phase 2 trial of SLS009 in first-line AML dosing patients; topline data expected in Q4 2026.
- R&D expenses $5.1M (up from $3.2M); G&A $4.1M (up from $2.9M) driven by BLA preparation and professional fees.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1390478/000139047826000009/0001390478-26-000009-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1390478/000139047826000009/sls-20260512.htm
  HTML page:      https://secwatch.observer/filing/0001390478-26-000009

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer